We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+5.08%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.49B
AUM Growth
+$37.4M
Cap. Flow
-$505M
Cap. Flow %
-20.29%
Top 10 Hldgs %
34.18%
Holding
156
New
33
Increased
30
Reduced
32
Closed
28

Top Buys

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$84.9M
2
EHTH icon
eHealth
EHTH
+$41.7M
3
KERX
Keryx Biopharmaceuticals Inc
KERX
+$35.2M
4
AGN
Allergan Inc
AGN
+$34M
5
ITMN
INTERMUNE INC
ITMN
+$26.9M

Top Sells

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$87.6M
2
LH icon
Labcorp
LH
+$56.3M
3
MRK icon
Merck
MRK
+$27.1M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$26.4M
5
DGX icon
Quest Diagnostics
DGX
+$25.5M

Sector Composition

Rank Sector Weight
1 Healthcare 42.33%
2 Financials 2.57%
3 Technology 1.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUXL
1
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$126M 5.06%
6,267,382
+3,700,677
+144% +$84.9M
ITMN
2
DELISTED
INTERMUNE INC
ITMN
$102M 4.11%
2,315,521
+731,579
+46% +$26.9M
AVDL
3
DELISTED
Avadel Pharmaceuticals
AVDL
$78.9M 3.17%
5,258,475
– –
AGN
4
DELISTED
Allergan Inc
AGN
$73.5M 2.95%
434,199
+218,563
+101% +$34M
NXTM
5
DELISTED
NxStage Medical Inc.
NXTM
$70.4M 2.83%
4,899,721
+1,098,546
+29% +$14.3M
KERX
6
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$59.7M 2.4%
3,884,409
+2,481,304
+177% +$35.2M
ARRY
7
DELISTED
Array Biopharma Inc
ARRY
$55.7M 2.24%
12,205,673
– –
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$54.8M 2.2%
2,428,569
– –
EHTH icon
9
eHealth
EHTH
$47.3M
$50.2M 2.02%
1,323,391
+1,052,391
+388% +$41.7M
UAM
10
DELISTED
Universal American Corp
UAM
$48.1M 1.93%
5,771,737
+1,170,744
+25% +$8.88M
INFI
11
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$46.8M 1.88%
3,674,838
-769,189
-17% -$8.01M
ASPX
12
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$44.2M 1.78%
1,984,038
-4,952
-0.2% -$108K
HCA icon
13
PUT
HCA Healthcare
HCA
$82.3B
$42.3M 1.7%
+750,000
New +$39.6M
BLUE
14
DELISTED
bluebird bio
BLUE
$41.5M 1.67%
83,011
+51,014
+159% +$16.4M
DVA icon
15
DaVita
DVA
$15.2B
$41M 1.65%
566,588
+218,577
+63% +$15.2M
HUM icon
16
CALL
Humana
HUM
$48B
$35.8M 1.44%
280,000
-1,000,000
-78% -$118M
DYAX
17
DELISTED
DYAX CORPORATION
DYAX
$35.7M 1.43%
3,717,013
-69,465
-2% -$529K
THC icon
18
PUT
Tenet Healthcare
THC
$16.8B
$35.2M 1.42%
+750,000
New +$33.9M
CI icon
19
PUT
Cigna
CI
$74.5B
$34.5M 1.39%
+375,000
New +$32.2M
AERI
20
DELISTED
Aerie Pharmaceuticals
AERI
$33.5M 1.35%
1,350,850
+785,670
+139% +$13.6M
ABBV icon
21
AbbVie
ABBV
$450B
$30.6M 1.23%
541,400
-483,600
-47% -$25.4M
AET
22
PUT
DELISTED
Aetna Inc
AET
$30.4M 1.22%
+375,000
New +$28.4M
PACB icon
23
Pacific Biosciences
PACB
$447M
$29M 1.17%
4,695,203
-710,907
-13% -$3.56M
MCK icon
24
McKesson
MCK
$98.5B
$27.9M 1.12%
150,000
-13,000
-8% -$2.31M
RNA
25
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$27.8M 1.12%
2,206,119
-1,005,253
-31% -$8.16M
1
2 3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2014 Portfolio in Review

As of Q2 2014, Deerfield Management held 156 positions worth $2.49B, up 1.5% from $2.45B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Deerfield Management withdrew a net $505M in Q2 2014, closing 28 positions and reducing 32 holdings. Its most notable exit was Merck, an estimated $27.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, down from 44% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK worth $23.1M.

  • Deerfield Management's largest Q2 2014 buy was TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK: 1,482,666 shares worth $23.1M.
  • Deerfield Management added most to AUXILIUM PHARAMCEUTICALS INC in Q2 2014, an estimated $84.9M increase.
  • Deerfield Management's biggest Q2 2014 reduction was QUESTCOR PHARMA INC, cutting an estimated $87.6M.
  • Deerfield Management fully exited Merck in Q2 2014, selling an estimated $27.1M.
  • Deerfield Management's ten largest holdings make up 34% of its $2.49B portfolio in Q2 2014.
  • Deerfield Management opened 33 new positions and closed 28 in Q2 2014.
  • Deerfield Management's portfolio value rose 1.5% quarter-over-quarter to $2.49B.

Based on Deerfield Management's 13F filing for Q2 2014, filed 14 Aug 2014.